Understanding how Sanger sequencing & fragment analysis are powering infectious disease research today

Infectious diseases present a great challenge to global health and the global economy as highlighted by the 2020 SARS-CoV-2 pandemic. Sanger sequencing and fragment analysis using gold-standard capillary electrophoresis (CE) technology plays a vital role across the spectrum from discovery of the infectious agent to cure due its flexibility, simple workflow, and accuracy for focused sequence analysis. Dr. Archana Gupta discusses how CE enables pathogen identification and surveillance, characterization of antibiotic resistance conferred through genetic evolution, and drug discovery and vaccine development against a variety of infectious agents.

Key topics include:

  • Application of Sanger sequencing and fragment analysis in SARS-CoV-2 surveillance, antiviral drug development and mRNA vaccine QC
  • Characterization of HIV genome mutations leading to drug resistance and durable cure through CRISPR gene editing
  • Understanding the microbiome and its influence on infectious disease pathology
  • Benefits of the latest generation CE-based genetic analyzer, the SeqStudio Flex analyzer, in infectious disease research and therapeutic development


Dr. Archana Gupta

Dr. Archana Gupta
Staff Scientist
Genetic Sciences Division - Thermo Fisher Scientific

Please fill out the form below to view this on-demand webinar.

(*Indicates a mandatory field)

Are you interested in a quote or demo for a member of the SeqStudio family of genetic analyzers?
Instrument DemoQuote
SeqStudio 8 Flex Genetic Analyzer
SeqStudio 24 Flex Genetic Analyzer
SeqStudio (4 capillary) Genetic Analyzer